Is there a role for early chemotherapy in the management of pituitary adenomas? Review uri icon

Overview

MeSH Major

  • Adenoma
  • Antineoplastic Agents
  • Dacarbazine
  • Pituitary Neoplasms

abstract

  • Pituitary adenomas are benign intracranial neoplasms that are frequently well-controlled with standard treatments that include surgical resection, radiotherapy, and agents that modulate hormonal excess. Unfortunately, a subset of patients remains uncontrolled or develops complications from these interventions. For these patients, chemotherapy is an additional treatment option that could improve outcomes. Temozolomide is an oral chemotherapy with a favorable side-effect profile that has shown activity against pituitary adenomas. Its non-overlapping toxicity and ability to induce rapid tumor regression renders it a potentially important adjunctive treatment. In patients with tumors that cannot be optimally addressed with standard treatments, there may be a role for early initiation of temozolomide.

publication date

  • October 2016

Research

keywords

  • Review

Identity

Language

  • eng

PubMed Central ID

  • PMC5035521

Digital Object Identifier (DOI)

  • 10.1093/neuonc/now059

PubMed ID

  • 27106409

Additional Document Info

start page

  • 1350

end page

  • 6

volume

  • 18

number

  • 10